Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders

Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis.

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

August 9, 2017
Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference

August 7, 2017
Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results

July 26, 2017
Global Blood Therapeutics Announces New Employment Inducement Grants

Read More News

Associated Team Members

Kevin Starr

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.

Glenn Pierce, M.D., Ph.D.